Aspirin use associated with an increased risk of upper gastrointestinal (GI) complications.
Proton pump inhibitors (PPIs) decrease the risk of upper gastrointestinal complications among aspirin users.
The distribution of risk factors for upper gastrointestinal complications and proton pump inhibitors utilization among aspirin users remains uncharacterized.
Dr Targownik and colleagues from Canada determined the prevalence and predictors of proton pump inhibitors use in high-risk aspirin users.
|Only 23% of subjects with additional upper GI complication risk factors were prescribed a PPI|
|Alimentary Pharmacology & Therapeutics|
The team used questionnaires and administrative records to collect information on aspirin and proton pump inhibitor utilization.
The research team also identified risk factors for upper gastrointestinal complications from a stratified random sample of subjects with established cardiovascular disease.
The team calculated the proportion of aspirin users with upper gastrointestinal complication risk factors.
The researchers then determined the prevalence of proton pump inhibitors use among aspirin users with risk factors.
The team used regression analysis to determine predictors of proton pump inhibitors use among aspirin users.
The the overall response rate was 35%, of whom 86% were regular aspirin users.
The researchers found that 71% of aspirin users had at least 1 risk factor, in addition to cardiac disease, for the development of upper gastrointestinal complications.
A history of upper gastrointestinal complication was predictive of proton pump inhibitors use.
However, 44% of aspirin users with a prior history of upper gastrointestinal complications did not receive a concomitant proton pump inhibitors.
The research team noted that only 23% of subjects with additional upper gastrointestinal complication risk factors were prescribed a proton pump inhibitor.
Dr Targownik's team concluded, "There is a high prevalence of upper gastrointestinal complication risk factors among aspirin users, and many are not prescribed proton pump inhibitors as a gastroprotective strategy."